洪姗,张怡欣,陈菲菲

• 1:浙江大学医学院附属第一医院临床药学部

摘要(Abstract)：

非酒精性脂肪性肝病(NAFLD)是一种与胰岛素抵抗和遗传易感性密切相关的代谢应激性肝脏损伤，与糖尿病的发生发展密切相关。近年来大量研究发现，新型糖尿病降糖药物[包括胰高血糖素样肽-1受体(GLP-1R)激动剂、二肽基肽酶-4(DPP-4)抑制剂、钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂等]对NAFLD具有良好的治疗效果。因此，本文综述了新型糖尿病降糖药物治疗NAFLD的研究进展，主要包括GLP-1R激动剂、肠抑胃肽(GIP)/GLP-1双重受体激动剂、GLP-1/胰高血糖素(GCG)双重受体激动剂、GLP-1/GIP/GCG三重受体激动剂、DPP-4抑制剂、SGLT2抑制剂等，以期为NAFLD的临床治疗与新药研发提供重要的理论指导与研究价值。

关键词(KeyWords)： 非酒精性脂肪性肝病;代谢相关性脂肪性肝病;糖尿病;治疗药物

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助项目(No.82204473);; 浙江省医药卫生科技计划项目(No.2022KY739)

作者(Author): 洪姗,张怡欣,陈菲菲

参考文献(References)：

• [1]Thomas JA，Kendall BJ，El-Serag HB，et al.Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease[J].Lancet Gastroenterol Hepatol，2024，9(2)：159-169.
• [2]Gofton C，Upendran Y，Zheng MH，et al.MAFLD：how is it different from NAFLD?[J].Clin Mol Hepatol，2023，29：17-31.
• [3]Keam SJ.Resmetirom：first approval[J].Drugs，2024，84(6)：729-735.
• [4]Targher G，Corey KE，Byrne CD，et al.The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments[J].Nat Rev Gastroenterol Hepatol，2021，18(9)：599-612.
• [5]Mantovani A，Byrne CD，Targher G.Efficacy of peroxisome proliferator-activated receptor agonists，glucagon-like peptide-1 receptor agonists，or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease：a systematic review[J].Lancet Gastroenterol Hepatol，2022，7(4)：367-378.
• [6]Younossi ZM，Golabi P，Paik JM，et al.The global epidemiology of nonalcoholic fatty liver disease(NAFLD)and nonalcoholic steatohepatitis(NASH)：a systematic review[J].Hepatology，2023，77(4)：1335-1347.
• [7]Handelsman Y，Anderson JE，Bakris GL，et al.DCRM 2.0：multispecialty practice recommendations for the management of diabetes，cardiorenal，and metabolic diseases[J].Metabolism，2024，159：155931.
• [8]Mantovani A，Petracca G，Beatrice G，et al.Non-alcoholic fatty liver disease and risk of incident diabetes mellitus：an updated meta-analysis of 501022 adult individuals[J].Gut，2021，70(5)：962-969.
• [9]Liu Y，Sun ZY，Dong RX，et al.Rutin ameliorated lipid metabolism dysfunction of diabetic NAFLD via AMPK/SREBP1 pathway[J].Phytomedicine，2024，126：155437.
• [10]Drucker DJ.The biology of incretin hormones[J].Cell Metab，2006，3：153-165.
• [11]Goldenberg RM，Gilbert JD，Manjoo P，et al.Management of type 2 diabetes，obesity，or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists[J].Obes Rev，2024，25(3)：e13663.
• [12]Douros JD，Mokrosinski J，Finan B.The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines[J].J Endocrinol，2024，261(2)：e230226.
• [13]Ying ZX，Eenige RV，Ge XK，et al.Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE3-Leiden.CETP mice[J].EBioMedicine，2023，93：104684.
• [14]Hartman ML，Sanyal AJ，Loomba R，et al.Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes[J].Diabetes Care，2020，43(6)：1352-1355.
• [15]Quinones M，Ferno J，Dieguez C，et al.Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives[J].Expert Opin Drug Discov，2019，14(5)：421-431.
• [16]Kaya E，Yilmaz Y，Alkhouri N.Survodutide in MASH：bridging the gap between hepatic and systemic metabolic dysfunction[J].Expert Opin Investig Drugs，2024，33(12)：1167-1176.
• [17]Singh A，Sohal A，Batta A.GLP-1，GIP/GLP-1，and GCGR/GLP-1 receptor agonists：novel therapeutic agents for metabolic dysfunction-associated steatohepatitis[J].World J Gastroenterol，2024，30(48)：5205-5211.
• [18]Aso Y，Kato K，Sakurai S，et al.Impact of dapagliflozin，an SGLT2 inhibitor，on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease[J].Int J Clin Pract，2019，73(5)：e13335.
• [19]Conarello SL，Li ZH，Ronan J，et al.Mice lacking dipeptidyl peptidaseⅣare protected against obesity and insulin resistance[J].Proc Natl Acad Sci USA，2003，100：6825-6830.
• [20]Fu ZD，Cai XL，Yang WJ，et al.Novel glucose-lowering drugs for non-alcoholic fatty liver disease[J].World J Diabetes，2021，12(1)：84-97.
• [21]Natale P，Tunnicliffe DJ，Toyama T，et al.Sodium-glucose co-transporter protein 2(SGLT2)inhibitors for people with chronic kidney disease and diabetes[J].Cochrane Database Syst Rev，2024，5(5)：CD015588.
• [22]Mirarchi L，Amodeo S，Citarrella R，et al.SGLT2 inhibitors as the most promising influencers on the outcome of non-alcoholic fatty liver disease[J].Int J Mol Sci，2022，23(7)：3668.
• [23]Khoo J，Hsiang JC，Taneja R，et al.Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease[J].Liver Int，2019，39(5)：941-949.
• [24]Guo W，Tian WJ，Lin L，et al.Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks：a randomized placebo-controlled trial[J].Diabetes Res Clin Pract，2020，170：108487.
• [25]Zhou JY，Poudel A，Welchko R，et al.Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways[J].Eur J Pharmacol，2019，861：172594.
• [26]Liao ZL，Huang LZ，Chen J，et al.Liraglutide improves nonalcoholic fatty liver disease in diabetic mice by activating autophagy through AMPK/mTOR signaling pathway[J].Diabetes Metab Syndr Obes，2024，17：575-584.
• [27]Zhang X，Coker OO，Chu ES，et al.Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites[J].Gut，2021，70(4)：761-774.
• [28]Moreira GV，Azevedo FF，Ribeiro LM，et al.Liraglutide modulates gut microbiota and reduces NAFLD in obese mice[J].J Nutr Biochem，2018，62：143-154.
• [29]Liu L，Yan HM，Xia MF，et al.Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes[J].Hepatology，2019，70(2)：711-724.
• [30]Unsal IO，Calapkulu M，Sencar ME，et al.Evaluation of NAFLD fibrosis，FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease[J].Sci Rep，2022，12(1)：283.
• [31]Saad ZA，Khodeer DM，Zaitone SA，et al.Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling：comparison to metformin[J].Life Sci，2020，253：117725.
• [32]Lyu J，Imachi H，Fukunaga K，et al.Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes[J].Mol Metab，2020，34：16-26.
• [33]林楚曼，方俊博，向倩如，等.Exendin-4通过促进自噬减少非酒精性脂肪性肝病细胞模型的脂质沉积[J].南方医科大学学报，2021，41(7)：1073-1078.
• [34]Ibrahim SS，Ibrahim RS，Arabi B，et al.The effect of GLP-1R agonists on the medical triad of obesity，diabetes，and cancer[J].Cancer Metastasis Rev，2024，43(4)：1297-1314.
• [35]Newsome PN，Sanyal AJ，Engebretsen KA，et al.Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis：baseline characteristics and design of the phase 3 essence trial[J].Aliment Pharmacol Ther，2024，60(11-12)：1525-1533.
• [36]Mao TH，Zhang CX，Yang S，et al.Semaglutide alters gut microbiota and improves NAFLD in db/db mice[J].Biochem Biophys Res Commun，2024，710：149882.
• [37]Kuchay MS，Krishan S，Mishra SK，et al.Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD：randomised controlled trial(D-lift trial)[J].Diabetologia，2020，63(11)：2434-2445.
• [38]Lee J，Hong SW，Kim MJ，et al.Dulaglutide ameliorates palmitic acid-induced hepatic steatosis by activating FAM3A signaling pathway[J].Endocrinol Metab，2022，37(1)：74-83.
• [39]Sachs S，Niu L，Geyer P，et al.Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice[J].Diabetes Obes Metab，2021，23(1)：195-207.
• [40]Frias JP，Nauck MA，Van J，et al.Efficacy and safety of LY3298176，a novel dual GIP and GLP-1 receptor agonist，in patients with type 2 diabetes：a randomised，placebo-controlled and active comparator-controlled phase 2 trial[J].Lancet，2018，392(10160)：2180-2193.
• [41]Frias JP，Davies MJ，Rosenstock J，et al.Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J].N Engl J Med，2021，385：503-515.
• [42]Hartman ML，Sanyal AJ，Loomba R，et al.Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes[J].Diabetes Care，2020，43(6)：1352-1355.
• [43]Gastaldelli A，Cusi K，Lando LF，et al.Effect of tirzepatide versus insulin degludecon liver fat content and abdominal adipose tissue in people with type 2 diabetes(surpass-3 MRI)：a substudy of the randomised，open-label，parallel-group，phase 3 surpass-3 trial[J].Lancet Diabetes Endocrinol，2022，10：393-406.
• [44]Jastreboff AM，Kaplan LM，Frias JP，et al.Retatrutide phase 2 obesity trial investigators：triple-hormone-receptor agonist retatrutide for obesity-a phase 2 trial[J].N Engl J Med，2023，389：514-526.
• [44]Abbasi J.New weight loss drugs make headlines at diabetes meeting[J].JAMA，2023，330：399-400.
• [45]Boland ML，Laker RC，Mather K，et al.Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis[J].Nat Metab，2020，2(5)：413-431.
• [46]Parker VER，Robertson D，Erazo-Tapia E，et al.Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes[J].Nat Metab，2023，5(12)：2086-2093.
• [47]Marcondes-de-Castro IA，Oliveira TF，Spezani R，et al.Cotadutide effect in liver and adipose tissue in obese mice[J].J Mol Endocrinol，2023，70(3)：e220168.
• [48]Sanyal AJ，Bedossa P，Fraessdorf M，et al.A phase 2 randomized trial of survodutide in MASH and fibrosis[J].N Engl J Med，2024，391(4)：311-319.
• [49]Lawitz EJ，Fraessdorf M，Neff GW，et al.Efficacy，tolerability and pharmacokinetics of survodutide，a glucagon/glucagon-like peptide-1 receptor dual agonist in cirrhosis[J].J Hepatol，2024，81(5)：837-846.
• [50]Elfeki MA，Alkhouri N.Triple-hormone-receptor agonist retatrutide for obesity[J].N Engl J Med，2023，389(17)：1629.
• [51]Jastreboff AM，Kaplan LM，Frias JP，et al.Triple-hormone-receptor agonist retatrutide for obesity-a phase 2 trial[J].N Engl J Med，2023，389(6)：514-526.
• [52]Jall S，Sachs S，Clemmensen C，et al.Monomeric GLP-1/GIP/glucagon triagonism corrects obesity，hepatosteatosis，and dyslipidemia in female mice[J].Mol Metab，2017，6(5)：440-446.
• [53]Khan RS，Bril F，Cusi K，et al.Modulation of insulin resistance in nonalcoholic fatty liver disease[J].Hepatology，2019，70(2)：711-724.
• [54]Iwasaki T，Yoneda M，Inamori M，et al.Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus[J].Hepatogastroenterology，2011，58：2103-2105.
• [55]Ren J，Wang XY，Yee C，et al.Sitagliptin is more effective than gliclazide in preventing pro-fibrotic and pro-inflammatory changes in a rodent model of diet-induced non-alcoholic fatty liver disease[J].Molecules，2022，27(3)：727.
• [56]Samano-Hernandez L，Fierro R，Marchal A，et al.Beneficial and deleterious effects of sitagliptin on a methionine/choline-deficient diet-induced steatohepatitis in rats[J].Biochimie，2021，181：240-248.
• [57]Tobita H，Sato S，Yazaki T，et al.Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver[J].Mol Med Rep，2018，17(5)：6840-6846.
• [58]Chen L，Zhang XJ，Zhang L，et al.Effect of saxagliptin，a dipeptidyl peptidase 4 inhibitor，on non-alcoholic fatty liver disease[J].Diabetes Metab Syndr Obes，2020，13：3507-3518.
• [59]Hussain M，Majeed Babar MZ，Hussain MS，et al.Vildagliptin ameliorates biochemical，metabolic and fatty changes associated with non alcoholic fatty liver disease[J].Pak J Med Sci，2016，32(6)：1396-1401.
• [60]Mantovani A，Petracca G，Csermely A，et al.Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease：a meta-analysis of randomized controlled trials[J].Metabolites，2020，11(1)：22.
• [61]Arase Y，Shiraishi K，Anzai K，et al.Effect of sodium glucose co-transporter 2 inhibitors on liver fat mass and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus[J].Clin Drug Investig，2019，39(7)：631-641.
• [62]Shiba K，Tsuchiya?K，Komiya C，et al.Canagliflozin，an SGLT2 inhibitor，attenuates the development of hepatocellular carcinoma in a mouse model of human NASH[J].Sci Rep，2018，8(1)：2362.
• [63]Lin XF，Cui XN，Yang J，et al.SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3，suppressing glycolysis and modulating macrophage polarization[J].Acta Pharmacol，2024，45(12)：2579-2597.
• [64]Huang SH，Wu BB，He YZ，et al.Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway[J].Hepatol Commun，2023，7(3)：e0045.
• [65]Luo JY，Sun PB，Wang YY，et al.Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway[J].Eur J Pharmacol，2021，907：174304.
• [66]Shen YF，Cheng LD，Xu MX，et al.SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis[J].Metabolism，2023，146：155657.
• [67]Radlinger B，Ress C，Folie S，et al.Empagliflozin protects mice against diet-induced obesity，insulin resistance and hepatic steatosis[J].Diabetologia，2023，66(4)：754-767.
• [68]Takahashi H，Kessoku T，Kawanaka M，et al.Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD[J].Hepatol Commun，2022，6(1)：20-132.
• [69]Morishita A，Tadokoro T，Fujihara S，et al.Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model[J].PLoS One，2022，17(2)：e0261310.
• [70]Chiang H，Lee JC，Huang HC，et al.Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice[J].Br J Pharmacol，2020，177(2)：239-253.
• [71]Sumida Y，Yoneda M，Tokushige K，et al.Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis[J].Int J Mol Sci，2020，21(6)：1907.
• [72]Kahl S，Ofstad AP，Zinman B，et al.Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes[J].Diabetes Obes Metab，2022，24(6)：1061-1071.
• [73]Rosenstock J，Wysham C，Frias JP，et al.Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes(SURPASS-1)：a double-blind，randomised，phase 3 trial[J].Lancet，2021，398(10295)：143-155.
• [74]Yan JH，Yao B，Kuang HY，et al.Liraglutide，sitagliptin，and insulin glargine added to metformin：the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J].Hepatology，2019，69(6)：2414-2426.
• [75]Gastaldelli A，Repetto E，Guja C，et al.Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes[J].Diabetes Obes Metab，2020，22(3)：393-403.